Get the Stockscreener App
43.42
2.70%
1.14
Nektar Therapeutics stock is traded at $43.42, with a volume of 685.81K.
It is up +2.70% in the last 24 hours and down -20.84% over the past month.
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
See More
Previous Close:
$42.28
Open:
$42.49
24h Volume:
685.81K
Relative Volume:
0.83
Market Cap:
$883.23M
Revenue:
$90.12M
Net Income/Loss:
$-276.06M
P/E Ratio:
-29.74
EPS:
-1.46
Net Cash Flow:
$-193.47M
1W Performance:
-2.41%
1M Performance:
-20.84%
6M Performance:
+70.07%
1Y Performance:
+4,418%
1-Day Range:
$41.51
$44.27
1-Week Range:
$41.32
$44.40
52-Week Range:
$0.432
$66.92
Nektar Therapeutics Stock (NKTR) Company Profile
Name
Nektar Therapeutics
Sector
Industry
Phone
(415) 482-5300
Address
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Compare NKTR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NKTR
Nektar Therapeutics
|
43.42 | 860.04M | 90.12M | -276.06M | -193.47M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-26-25 | Initiated | Citigroup | Buy |
| Jun-24-25 | Reiterated | BTIG Research | Buy |
| Jun-24-25 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-25 | Upgrade | Jefferies | Hold → Buy |
| Mar-14-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-08-25 | Initiated | B. Riley Securities | Buy |
| Dec-10-24 | Initiated | H.C. Wainwright | Buy |
| Nov-04-24 | Initiated | Piper Sandler | Overweight |
| Sep-30-24 | Resumed | BTIG Research | Buy |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Nov-09-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| May-10-23 | Upgrade | Jefferies | Underperform → Hold |
| Feb-24-23 | Downgrade | Jefferies | Hold → Underperform |
| Aug-08-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-31-22 | Resumed | Jefferies | Hold |
| Apr-18-22 | Downgrade | Goldman | Neutral → Sell |
| Mar-15-22 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-15-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-14-22 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-14-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Mar-14-22 | Downgrade | Stifel | Buy → Hold |
| Mar-14-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-09-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-08-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Sep-10-21 | Initiated | BofA Securities | Neutral |
| Jun-28-21 | Upgrade | Stifel | Hold → Buy |
| May-18-21 | Resumed | Goldman | Neutral |
| Feb-22-21 | Downgrade | The Benchmark Company | Buy → Hold |
| Jan-06-21 | Initiated | Stifel | Hold |
| Sep-14-20 | Initiated | JP Morgan | Neutral |
| Jun-10-20 | Downgrade | CFRA | Hold → Sell |
| May-12-20 | Reiterated | H.C. Wainwright | Neutral |
| Apr-22-20 | Initiated | The Benchmark Company | Buy |
| Mar-30-20 | Upgrade | Goldman | Sell → Neutral |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Feb-03-20 | Upgrade | Mizuho | Neutral → Buy |
| Oct-24-19 | Initiated | Oppenheimer | Perform |
| Oct-08-19 | Downgrade | Goldman | Buy → Sell |
| Aug-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-09-19 | Downgrade | Jefferies | Buy → Hold |
| Aug-09-19 | Downgrade | Mizuho | Buy → Neutral |
| Mar-15-19 | Initiated | SVB Leerink | Mkt Perform |
| Dec-13-18 | Initiated | Goldman | Buy |
| Jun-11-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-04-18 | Reiterated | H.C. Wainwright | Buy |
| Apr-20-18 | Initiated | Seaport Global Securities | Buy |
| Apr-13-18 | Resumed | Piper Jaffray | Overweight |
| Apr-06-18 | Reiterated | Mizuho | Buy |
| Apr-02-18 | Resumed | H.C. Wainwright | Buy |
View All
Nektar Therapeutics Stock (NKTR) Latest News
Nektar Therapeutics: Can a Beaten-Down Biotech Still Surprise Wall Street? - AD HOC NEWS
How Nektar Therapeutics stock reacts to global recession fearsGrowth vs. Value Investing & Optimize Entry & Exit With Smart Signals - bollywoodhelpline.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar TherapeuticsNKTR - PR Newswire
Drugs to Watch in 2026 - Dermatology Times
Nektar Therapeutics Stock Analysis and ForecastStock Screening Results & Outstanding Return Portfolio - earlytimes.in
Moody Aldrich Partners LLC Buys 28,304 Shares of Nektar Therapeutics $NKTR - MarketBeat
Top 10 skin disorder stories of 2025 - Healio
Simplify Asset Management Inc. Buys 35,176 Shares of Nektar Therapeutics $NKTR - MarketBeat
Nektar Therapeutics (NASDAQ:NKTR) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Aug Wrap: Why Nektar Therapeutics stock could rally in 2025Earnings Growth Summary & Risk Adjusted Buy/Sell Alerts - moha.gov.vn
Dermatology Times 2025 Year in Review: Atopic Dermatitis - Dermatology Times
Nektar Therapeutics Shares Rise After Positive Asthma Data in Atopic Dermatitis Patients - MSN
Brain Implants for Mental Health and Chinese Competition Expected to Shape BCI Advancements by 2026 - geneonline.com
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar - sharewise.com
Nektar Therapeutics (NKTR) price target increased by 14.31% to 109.43 - MSN
More Unpleasant Surprises Could Be In Store For Nektar Therapeutics' (NASDAQ:NKTR) Shares After Tumbling 25% - simplywall.st
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow - Finviz
Nektar Therapeutics (NKTR) CEO reports RSU and stock option grants - Stock Titan
Will Nektar Therapeutics (ITH0) stock outperform energy sector in 2025Earnings Miss Alerts & Maximize ROI With Proven Growth Stocks - Bollywood Helpline
Published on: 2025-12-23 18:23:01 - moha.gov.vn
Nektar Therapeutics announces phase 2b trial results - MSN
Atopic Dermatitis in 2025: Year in Review - HCPLive
Nektar Therapeutics (NKTR) Stock Slides Despite Analyst Optimism On Alopecia Data - Benzinga
Transformative Advances This Year and Beyond - Dermatology Times
Strong REZOLVE-AA Study Results Drive Analyst Confidence in Nektar Therapeutics (NKTR) - Insider Monkey
Is Nektar Therapeutics (ITH0) stock ideal for retirement investors2025 Trading Volume Trends & Accurate Buy Signal Alerts - ulpravda.ru
Nektar Therapeutics: Rezpeg's Phase 2b Alopecia Areata Results Leave Many Questions - Seeking Alpha
Why Analysts Think Nektar Therapeutics Could Be Undervalued After Rezpeg Trial Momentum Grows - Yahoo Finance
Machine Learning Tool vConTACT3 Developed to Enhance Global Virus Classification - geneonline.com
Is Nektar Therapeutics stock resilient to inflationMarket Movement Recap & Free Weekly Chart Analysis and Trade Guides - Улправда
Why analysts remain bullish on Nektar Therapeutics stockMarket Rally & Reliable Price Breakout Signals - DonanımHaber
Nektar Therapeutics Data from REZOLVE-AD Study Accepted for Late-Breaking Oral Presentation - MSN
Assessing Nektar Therapeutics (NKTR) Valuation After a Volatile Year and Recent Share Price Pullback - simplywall.st
Nektar Therapeutics Q3 2025 Earnings Preview - MSN
Oppenheimer maintains Outperform rating on Q32 Bio stock at $20 target - Investing.com
Nektar Therapeutics announces top-line results from alopecia areata study - PMLiVE
Nektar Therapeutics Price Target Raised to $118.00/Share From $100.00 by BTIG - 富途牛牛
Nektar Therapeutics Is Maintained at Buy by BTIG - 富途牛牛
Nektar Therapeutics stock price target raised to $135 at H.C. Wainwright on alopecia data - Investing.com Nigeria
Nektar Therapeutics: Alopecia Update And A Look At The Road Ahead For Rezpeg (NASDAQ:NKTR) - Seeking Alpha
Nektar Therapeutics (NASDAQ:NKTR) Shares Down 6.5%Should You Sell? - MarketBeat
Rezpegaldesleukin Demonstrates Proof of Concept in Phase 2b Trial for Severe Alopecia Areata - Patient Care Online
Jefferies Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $121 - news.futunn.com
Nektar Therapeutics to Advance Rezpeg into Phase III Trials for Alopecia Areata Despite Phase II Endpoint Miss - geneonline.com
Nektar Therapeutics Earnings Notes - Trefis
BTIG Research Issues Positive Forecast for Nektar Therapeutics (NASDAQ:NKTR) Stock Price - MarketBeat
REZOLVE-AA: Phase 2b Data Released on Rezpegaldesleukin for Alopecia Areata - HCPLive
Nektar Digs Into Mid-Stage Data to Establish Alopecia Efficacy of Rezpeg - BioSpace
Nektar reports positive Ph IIb results in alopecia areata - The Pharma Letter
Promising Efficacy and Safety of Rezpegaldesleukin Positions Nektar Therapeutics as a Leader in Alopecia Areata Treatment - TipRanks
BTIG Maintains Nektar Therapeutics (NKTR) Buy Recommendation - Nasdaq
Nektar Therapeutics Stock (NKTR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Nektar Therapeutics Stock (NKTR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Wilson Mark Andrew | Chief Legal Officer |
Nov 25 '25 |
Sale |
54.28 |
630 |
34,196 |
21,585 |
| ROBIN HOWARD W | President & CEO |
Nov 25 '25 |
Sale |
54.28 |
2,207 |
119,796 |
54,245 |
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):